IE48521B1 - 6-trimethylsilyloxycarbonyl penicillanic acid esters and the production of penicillins therefrom - Google Patents

6-trimethylsilyloxycarbonyl penicillanic acid esters and the production of penicillins therefrom

Info

Publication number
IE48521B1
IE48521B1 IE1283/79A IE128379A IE48521B1 IE 48521 B1 IE48521 B1 IE 48521B1 IE 1283/79 A IE1283/79 A IE 1283/79A IE 128379 A IE128379 A IE 128379A IE 48521 B1 IE48521 B1 IE 48521B1
Authority
IE
Ireland
Prior art keywords
group
formula
compound
acid
reaction
Prior art date
Application number
IE1283/79A
Other versions
IE791283L (en
Original Assignee
Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/021,852 external-priority patent/US4240960A/en
Application filed by Bristol Myers Co filed Critical Bristol Myers Co
Publication of IE791283L publication Critical patent/IE791283L/en
Publication of IE48521B1 publication Critical patent/IE48521B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1896Compounds having one or more Si-O-acyl linkages

Abstract

Trimethylsilyl or another easily hydrolyzed ester of 6- trimethylsilyloxycarbonylaminopenicillanic acid was prepared by bubbling dry carbon dioxide into an anhydrous solution of the corresponding 6- trimethylsilylaminopenicillanate and found to be a useful intermediate in the production of penicillins, e.g., amoxicillin and ampicillin, by its acylation in anhydrous media with the appropriate acid chloride or acid chloride hydrochloride.

Description

The present invention relates to a new process for the production of antibacterial agents of the class commonly called semi-synthetic penicillins and, preferably, of the sub-class characterized by an α-amino group on the acyl sidechain at the 6-position as in ampicillin and amoxicillin.
The first commercial penicillin having an a-amino group on the 6-acylamino sidechain was ampicillin, which is 6-(D-a-amino-a-phenylacetamido)penicillanic acid (see U.S. Patent No. 2,985,648).
Amoxicillin is an antibacterial agent used in human therapy and marketed as the trihydrate of the free acid (i.e., the zwitterion). It is described, for example, in U.K. Patent Specification 978,178, J. Chem.
Soc. (London), pages 1920-1922 (1971) and Antimicrobial Agents and Chemotherapy - 1970, pages 407-430 (1971).
Its chemical name is 6-[D-a-amino-α-(p-hydroxyphenyl)acetamidoJpenicillanic acid.
The use of amino acid chloride hydrochlorides to make such penicillins was disclosed in the patent literature, e.g. in U.K. Patent No. 938,321 and Irish 8 5 21 Patent No. 27232 under anhydrous conditions (the latter utilized the protection during acylation of the carboxyl group of the 6-aminopenicillanic acid with a silyl group as was also disclosed in U.K. Patent No. 1,008,468 and U.S. Patent No. 3,249,622) and in U.K. Patent No. 962,719 in cold aqueous acetone. These penicillins are amphoteric amino acids and use was therefore made in their isolation (e.g. as disclosed in U.S. Patent No. 3,157,640 and U.S. Patent No. 3,271,389) of certain aliphatic unsymmetrical branched chain secondary amines (often called liquid amine resins) which had previously been used in the isolation of 6-aminopenicillanic acid which is also an amphoteric amino acid (see U.S. Patent No. 3,008,956). Improved methods of isolating and purifying such penicillins were disclosed, e.g. in U.S. Patent No. 3,180,862 via β-naphthalene sulfonates and in U.S. Patent No. 3,198,804 via intermediate isolation and subsequent facile hydrolysis of hetacillin.
The use of a silyl group to protect the carboxyl group of a natural penicillin during chemical cleavage to 6-aminopenicillanic acid was disclosed in U.S. Patent No. 3,499,909. The use of silylated 6-aminopenicillanic acid during anhydrous acylation with amino acid chloride hydrochlorides was disclosed in numerous patents, e.g.
U.S. Patent No. 3,479,018; U.S. Patent No. 3,595,855; U.S. Patent No. 3,654,266; U.S. Patent No. 3,479,338 and U.S. Patent No. 3,487,073. Some of these patents also disclose use of liquid amine resins. See also U.S. Patents 3,912,719, 3,980,637 and 4,128,547.
U.K. Patent No. 1,339,605 contains various specific and detailed examples for preparing amoxicillin by the reaction of a silylated derivative of 6-aminopenicillanic acid with a reactive derivative (including the chloride hydrochloride) of D-(-)-a-amino-p-hydroxyphenylacetic acid in which the amino group is protected, thereafter removing the silyl group(s) by hydrolysis or alcoholysis and thereafter, when possible, recovering the amoxicillin, usually as the crystalline trihydrate. Thus crystalline amoxicillin was obtained in Example 1 by isoelectric precipitation from an aqueous solution, e.g. at pH 4.7. Purification was presumably achieved by this example by dissolving the crude product (before isoelectric precipitation) in water at an acidic pH such as 1.0 (e.g. in aqueous hydrochloric acid) in the presence of a water-immiscible organic solvent such as methyl isobutyl ketone (4-methylpentan-2-one). Much the same procedure was used in U.S. Patent No. 3,674,776.
There is provided by the present invention the process for the production of a conventional penicillin which comprises reacting a compound of the formula C-O-B wherein β is an easily cleavable ester protecting group, which is preferably selected from the group consisting of trimethylsilyl, benzhydryl, benzyl, p-nitrobenzyl, p-methoxybenzyl, trichloroethyl, phenacyl, acetonyl, methoxymethyl, 5indanyl, 3-phthalidyl, l-[(ethoxycarbonyl)oxy]ethyl,' 8 5 21 pivaloyloxymethyl and acetoxymethyl in an anhydrous inert organic solvent and preferably in methylene chloride, preferably in the presence of a weak base which is preferably propylene oxide and preferably at a temperature above -10° C., and more preferably in the range of -8* C. to 20° C., and more preferably in the range of 0° C. to 20° C., and most preferably at approximately 20° C., with approximately an equimolar weight of an acid chloride or chloride hydrochloride with the latter being preferably added in portions to the solution of the former, and then, if desired, converting group B to hydrogen.
A conventional penicillin as defined herein is one which has been described previously in the patent or scientific literature, including abstracts thereof.
There is also provided, according to the present invention, the process for the production of the compound of the formula II C-O-B wherein B is an easily cleavable ester protecting group, which is preferably selected from the group consisting of trimethylsilyl, benzhydryl, benzyl, p-nitrobenzyl, p-methoxybenzyl, trichloroethyl, phenacyl, acetonyl, methoxymethyl, 525 indanyl, 3-phthalidyl, 1-[Cethoxycarbonyl)oxy]ethyl, pivaloyloxymethyl and acetoxymethyl which comprises adding dry carbon dioxide as a gas to a solution of a compound having the formula wherein B has the same meaning as above, in an anhydrous inert organic solvent, preferably methylene chloride at room temperature or at a temperature in the range of 0° C. to 100° C. until completion of the reaction.
There is further provided as a preferred embodiment of the present invention the process for the production of a 6-a-aminoarylacetamidopenicillanic acid, preferably ampicillin or amoxicillin, which comprises reacting a compound of the formula , λ II /01¼ (CH_),Si-O-C-NH-CH—CH C 5 -3 3 II I^CH, -CH in an anhydrous inert organic solvent and preferably in methylene chloride, preferably in the presence of a weak base which is preferably propylene oxide and preferably at a temperature above -10° C., and more preferably in the range of -8° C. to 20° C., and more preferably in the range of 0° C. to 20° C. and most preferably of approximately 20° C., with approximately an equimolar weight of a D-(-)-a-aminoarylacetyl chloride hydrochloride, preferably D-(-)-2-phenylglycyl chloride hydrochloride or D-(-)-2-p-hydroxyphenylglycyl chloride hydrochloride respectively, with the latter being preferably added in portions to the solution of the former.
One of the surprising features of the new process is the stability of the anhydrous acylation solution.
This can be held for long periods of time even at room temperature without noticeable decomposition of the penicillin molecule. This is in contrast to the behavior of acylation solutions in heretofore described processes. This stability advantage allows us to carry out the acylation reaction at much higher temperatures (we used room temperature) than are normally employed in ampicillin manufacture which are normally less than 0° C. and typically about -10° C.
There is also provided as a preferred embodiment, the process for the production of the compound of the formula II / (CH^ )5Si-0-C-NH-CH—CH S, CH which comprises adding dry carbon dioxide as a gas to a solution of trimethylsilyl 6-trimethylsilylaminopenicillanate in an anhydrous inert organic solvent, prefarably methylene chloride, at room temperature or at a temperature in the range of 0° C. to 100° C. until completion of the reaction. 8 5 2 1 There is also provided as an embodiment of the present invention a compound having the formula wherein B is an easily cleavable ester protecting group or more preferably an easily cleavable ester protecting group selected from the group consisting of trimethylsilyl, benzhydryl, benzyl, p-nitrobenzyl, p-methoxybenzyl, trichloroethyl, phenacyl, acetonyl, methoxymethyl, 5indanyl, 3-phthalidyl, 1-[(ethoxycarbonyl)oxy]ethyl, pivaloyloxymethyl and acetoxymethyl.
There is further provided as a preferred embodiment the compound having the formula This compound is referred to herein by various trivial names such as bis silylated carbamate of 6-APA, SCA, 6-trimethylsilyloxycarbonylpenicillanic TMS ester and TMSOjC.APA.TMS.
The very existence of this compound is surprising in view of the well-known fact that reaction of 6-APA with carbon dioxide destroys the 6-APA and produces 8-hydroxypenicillanic acid as disclosed, for example, in U.S. 3,225,033.
A key to obtaining quantitative yields of 6trimethylsilyloxycarbonylaminopenicillanic acid trimethyl silyl ester (TMSC^C.APA.TMS) lies in completely producing the 6-APA bis TMS precursor in the first instance. This has been achieved by reacting 6-APA with hexamethyldisilazane (HMDS) as in the following schematic outline: 6-APA + HMDS + Imidazole P.eflux catalyst 6-8 hr. mole 1.1 mole 3-5 mole$ complete carboxyl silylation'' & ca 4065^ 6-1,Ή silylation.
Add 5 mole TMCS and reflux overnight TMSNH (6-APA.bis TMS) ''COgTMS Completion of the bis trimethylsilylation reaction can be readily followed using NMR. The 3_-trimethylsilyl20 oxycarbonyl group shows a methylsilyl singlet at 0.31 ppm (tetramethylsilane = 0) while the 6-trimethylsilylamine group shows a methylsilyl singlet at 0.09 ppm. 8 5 2 1 The 6-APA trimethylsilylation reaction has so far only been carried out in methylene chloride. However, other solvents may be used, e.g. acetonitrile, dimethylformamide or even HMDS itself.
Conversion of the trimethylsilylamino group to the trimethylsilyloxycarbonylamino group is readily achieved by bubbling dry CO 2 into the reaction solution. The conversion is easily followed by NMR because the trimethylsilylamino singlet at 0.09 ppm declines as a new singlet for the trimethylsilyloxycarbonylamino group appears at 0.27 ppm.
When the process of the present invention is used to produce ampicillin, ampicillin anhydrate, ampicillin trihydrate, amoxicillin and amoxicillin trihydrate, the final products are isolated and purified according to conventional methods well known in the art as illustrated by the disclosures of U.S. Patents 3,912,719, 3,980,637 and 4,128,547 and that of other patents and publications cited therein.
The acid chlorides used in the examples below can be replaced by a variety of other acid chlorides to produce conventional penicillins.
Thus the acyl halide may he chosen to introduce any desired acyl group at the 6-amino position as is well known in the art, e.g. U.S. 3,741,959. It is thus possible to introduce specific acyl radicals including, but not limited to, those defined in the following general formulae: (i) RuCnH2nCO- where Ru is aryl (carboxylic or heterocyclic), cycloalkyl, substituted aryl, substituted cycloalkyl, or a non-aromatic or mesoionic heterocyclic group, and n is an integer from 1-4. Examples of this group include phenylacetyl, substituted phenylacetyl, e.g. fluorophenylacetyl, nitrophenylacetyl, aminophenylacetyl, acetoxyphenylacetyl, methoxyphenylacetyl, methyl phenyl acetyl, or hydroxyphenylacetyl; Ν,Ν-bis (2chloroethyl)aminophenylpropionyl; thien-3-acetyl; 4-isoxazolyl and substituted 4-isoxazolylacetyl; pyridylacetyl; tetrazolylacetyl or a sydnoneacetyl group. The substituted 4-isoxazolyl group may be a 3-aryl-5-methyl isoxazol-4-yl group, the aryl group being, e.g. phenyl or halophenyl, e.g. chloro- or bromo- phenyl. An acyl group of this type is 3-o-chlorophenyl-5-methyl isoxazol4-yl-acetyl. (ii) <-·ηΗ2η+1<“θ- w^ere n ·*·3 an i-ntei?er from 1-7.
The alkyl group may be straight or branched, and if desired, may be interrupted by an oxygen or sulphur atom or substituted by, e.g. a cyano group. Examples of such groups include cyanoacetyl, hexanoyl, heptanoyl, octanoyl and butylthioacetyl. (iii) C H_ -.CO- where n is an integer from 2-7. n zn—1 The group may be straight or branched and, if desired, may be interrupted by an oxygen or a sulphur atom. An example of such a group is allylthioacetyl. (iv) Rv rH) -C-CCwhere Ru has the meaning defined under (i) and in addition may be benzyl, and RV and RW which may be the same or different each represent hydrogen, phenyl, benzyl, phenethyl or lower alkyl. Examples of such groups include n phenoxyacetyl, 2-phenoxy-2-phenylacetyl, 2-phenoxypropionyl, 2-phenoxybutyryl, benzy loxyacetyl, 2-methyl2-phenoxypropionyl, p-cresoxyacetyl and p-methylthiophenoxyacetyl. (v) Rv u I R S-C-COlw RW where RU has the meaning defined under (i) and, in V w addition, may be benzyl and R and R have the meanings defined under (iv). Examples of such groups include S-phenylthioacetyl, S-chlorophenylthioacetyl, S-fluorophenylthioacetyl, pyridylthioacetyl, and S-benzylthioacetyl. (vi) RUZ(Ci^J^CO- where Ru has the meaning defined under (i) and, in addition, may be benzyl, Z is an oxygen or sulphur atom and m is an integer from 2-5. An example of such a group is S-benzylthiopropionyl. (vii) RUCO- where Ru has the meaning defined under (i). Examples of such groups include benzoyl, substituted benzoyl (e.g. aminobenzoyl), 4-isoxazolyl- and substituted 4-isoxazolyl carbonyl, cyclopentanecarbonyl, sydone carbonyl, naphthoyl and substituted naphthoyl (e.g. 2-ethoxynaphthoyl) quinoxalinylcarbonyl and substituted quinoxalinylcarbonyl (e.g. 3-carboxy-2-quinoxalinylcarbonyl). Other possible substituents for benzoyl include alkyl, alkoxy, phenyl or phenyl substituted with carboxy, alkylamido, cycloalkylamido, allylamido, phenyl(lower)- alkylamido, morpholinocarbonyl, pyrrolidinocarbonyl, piperidinocarbonyl, tetrahydropyridino, furfurylamido or N-alkyl-N-anilino, or derivatives 8 5 21 thereof, and such substituents may be in the 2- or 2and 6-positions. Examples of such substituted benzoyl groups are 2,6-dimethoxybenzoyl, 2-biphenylcarbonyl, 2-methylamidobenzoyl and 2-carboxybenzoyl. Where the group Ru represents a substituted 4-isoxazolyl group, the substituents may be as set out above under (i). Examples of such 4-isoxazol groups are 3-phenyl-5-methylisoxazol-4-yl carbonyl, 3-o-chlorophenyl-5-methylisoxazol-4-yl carbonyl and 3-(2,6-dichlorophenyl)-5methylisoxazol-4-yl carbonyl. (viii) RU-^H-COX where Ru has the meaning defined under (1) and X is amino, substituted amino (e.g. acylamino or a group obtained by reacting the amino group and/or group(s) of the 6sidechain with an aldehyde or ketone, e.g. acetone, methylethylketone or ethyl acetoacetate), hydroxy, carboxy, esterified carboxy, triazolyl, tetrazolyl, cyano, halogeno, acyloxy, (e.g. formyloxy or lower alkanoyloxy) or etherified hydroxy group. Examples of such acyl groups are α-aminophenylacetyl, a-carboxyphenylacetyl and 2,2-dimethyl-5-oxo-4-phenyl-l-imidazolidinyl. (ix) Ry-C_COAz where Rx, Ry and Rz which may be the same or different may each represent lower alkyl, phenyl or substituted phenyl. An example of such an acyl group is triphenylcarbonyl . u 11 R-NH-Cwhere Ru has the meaning defined under (1) and in addition may be hydrogen, lower alkyl or halogen substituted lower alkyl, and Y represents oxygen or sulphur.
An example of such a group is Cl(CH2)2NHCO. where X has the meaning defined under (viii) above and n is an integer of from 1 to 4. An example of such an acyl group is 1-amino-cyclohexanecarbonyl. (xii) Amino acyl, for example RWCH(NH2).
(CH2)nCO where n is an integer from 1-10, or NH2· C H- Ar(CH-) CO, where m is zero or an integer from Π ζΠ Ζ ΙΠ w 1-10, and n is 0, 1 or 2, R is a hydrogen atom or an alkyl, aralkyl or carboxy group or a group as defined under RU above, and Ar is an arylene group, e.g. pphenylene or 1,4-naphthylene. Examples of such groups are disclosed in British Patent Specification No. 1,054,806. A group of this type is the p-aminophenylacetyl group. Other acyl groups of this type include those, e.g. δ-aminoadipoyl derived from naturally occurring amino acids and derivatives thereof, e.g. N-benzoyl-S-aminoadipoyl. (xiii) Substituted glyoxylyl groups of the formula RY.CO.CO- where Ry is an aliphatic, araliphatic or aromatic group, e.g. a thienyl group, a phenyl group, or a mono-, di- or tri-substituted phenyl group, the substituents being, for example, one or more halogen atoms (P, Cl, Br, or I), methoxy groups, methyl groups, or amino groups, or a fused benzene ring.
When the acyl group being introduced contains an amino group it may be necessary to protect this during the various reaction stages. The protecting group is conveniently one which can be removed by hydrolysis without affecting the rest of the molecule, especially the lactam and 6-amido linkages. The amine protecting group and the esterifying group at the 3-COOH position can be removed using the same reagent. An advantageous procedure is to remove both groups at the last stage in the sequence. Protected amine groups include urethane, arylmethyl (e.g. trityl) amino, arylmethyleneamino, sulphenylamino or enamine types. Enamine blocking groups are particularly useful in the case of o-aminomethylphenyl acetic acid. Such groups can in general be removed by one or more reagents selected from dilute mineral acids, e.g. dilute hydrochloric acid, concentrated organic acids, e.g. concentrated acetic acid, trifluoroacetic acid, and liquid hydrogen bromide at very low temperatures, e.g. -80°C. A convenient protecting group is the t-butoxycarbonyl group, which is readily removed by hydrolysis with dilute mineral acid, e.g. dilute hydrochloric acid, or preferably with a strong organic acid (e.g. formic acid or trifluoroacetic acid) e.g. at a temperature of 0-40°C., preferably at room temperature (15-25°C.). Another convenient protecting group is the 2,2,2-trichloroethoxycarbonyl group which may be split off by an agent such as zinc/acetic acid, zinc/formic acid, zinc/lower alcohols or zinc/ pyridine.
The NH2 group may also be protected as NH3+ by using the amino acid halide as an acid addition salt under conditions in which the amino group remains protonated.
The acid used to form the acid addition salt is preferably one having a pKa (in water at 25°C.) of / X+l, where X is the pKfl value (in water at 25°C.) of the carboxy groups of the amino acid; the acid is preferably monohydric. In practice the acid HQ (see below) will generally have a pK <3, preferably <1.
Particularly advantageous results have been found to accrue from the process according to the invention when the acyl halide is a salt of an amino acid halide.
Amino acid halides have the formula H2N-R1-COHal wherein R^ is a divalent organic group and Hal is chloride or bromide. Salts of such amino acid halides have the formula [HjN-Rj-COHal]+Q- wherein and Hal have the above defined meanings and 15 Q is the anion of the acid, HQ having a pKa as defined above. The acid HQ is preferably a strong mineral acid such as, for example, a hydrohalic acid such as hydrochloric acid or hydrobromic acid. An important amino acid halide, by reason of the valuable penicillin anti20 biotics which contain the group derived therefrom is D-N-(α-chlorocarbonyl-a-phenyl)-methylammonium chloride, D-[PhCH(NH3)COC1) Cl-, which is referred to herein as D-a-phenylglycylchloride hydrochloride for convenience.
Penicillins obtained by the process according to the invention and having the acylarnino group RUCH(NH2)CONH- where Ru has the above-defined meaning, may be 3 2 3 reacted with a ketone R .R CO where R and R are lower alkyl groups (C^-C^i, to yield compounds believed to contain the group: Compounds of this type include hetacillin, sarpicillin, p-hydroxyhetacillin and sarmoxicillin.
Also included herein and incorporated in full by reference are the acyl groups set forth in the U.S.
Patent 4,013,648 in columns 7-20 inclusive.
When the acylation process of the present invention is used to produce penicillins the final products are isolated and purified according to conventional methods well known in the art.
Preferred acyl chlorides used in the present invention to acylate a compound having the formula wherein A is (CHjJjSi- or an easily cleavable ester protecting group including the following: II a) A-Ci^C-Cl wherein A represents wherein R is hydrogen, hydroxy or methoxy and R' is hydrogen or methyl and the amino group is blocked, if desired, by conventional blocking groups including particularly by protonation; U) B-CH-C-C1-HCl wherein 3 represents NH_ or or Owherein R^ is hydrogen, hydroxy or acetoxy and R is 1 2 hydrogen, chloro or hydroxy when R is hydroxy and R is hydrogen when R1 is hydrogen or acetoxy; wherein R is phenyl, 4-hydroxyphenyl, 3,4-dihydroxyphenyl or cyclohexa-l,4-dien-l-yl; f) C2H5-N ο II ο II -C-NH-CH-C-C1 I R wherein R is phenyl, 4-hydroxyphenyl, 3,4-dihydroxyphenyl or cyclohexa-l,4-dien-l-yl; 0 II -C-NH-CH-C-C1 . h '0 wherein R phenyl or is phenyl, 4-hydroxyphenyl, cyclohexadien-l-yl 3,4-dihydroxy- wherem R1 is phenyl, 4-hydroxyphenyl, 3,4-dihydroxy2 phenyl or cyclohexadien-l-yl and R is hydrogen or hydroxy; , x „ I· j) i^C-S-CI^C-Cl; Vl ? ^-ch2c-ci; o , Il 1) NC-CH-C-C1; 8 5:: ι m) Ν 'S-CHgC-Cl; Ο , II η) Br-CH2C-Cl; Η2Ν ο) S •CH2C-C1 ρ) NIC-CH2-S-CH2-C-C1; S q) NH r>i s II HN-LL.C-C-C1 ’ H k-och3 r) CH=N-N M-C-NH-CH-C-C1 I R wherein R is phenyl, 4-hydroxyphenyl, 3,4-dihydroxyphenyl or cyclohexadien-l-yl; ll x It ) A-N IJ-C-NH-CH-C-C1 \ / I V_7 wherein A is hydrogen or alkyl of 1 to 4 carbon atoms or CH3SO2~, X is oxygen or sulfur and R is phenyl, 4-hydroxy phenyl, 3,4-dihydroxyphenyl or cyclohexa-1,4-dien-1-yl; -0-C—C-Cl CH3 wherein R is hydrogen or methyl; 2 wherein each of R and R is hydrogen, chloro or fluoro; , ii x) B-CH-C-C1-HCl wherein 3 represents NH I C»NH R2 Ct 2 wherein R is hydrogen, hydroxy or acetoxy and R is 2 hydrogen, chloro or hydroxy when R is hydroxy and R is hydrogen when R^ is hydrogen or acetoxy; 8 5 21 ii B-CH-C-C1 I NH I NKR or wherein B represents or 2 wherein R is hydrogen, hydroxy or acetoxy and R is 2 hydrogen, chloro or hydroxy when R is hydroxy and R is hydrogen when R^ is hydrogen or acetoxy, and R is hydrogen or cyanomethyl; ff) gg) CH2=CH-CH2-S-CH2-C-C1 hh) '6.H5 'C-Cl II ii) B-CH-$-Cl wherein B represents NH I O=C-HH-C' NH χΝΗ„ R2 or or 2 wherein R is hydrogen, hydroxy or acetoxy and R is 2 hydrogen, chloro or hydroxy when R is hydroxy and R is hydrogen when R^ is hydrogen or acetoxy; 11) jj) kk) II C-Cl wherein R is hydrogen or methyl. ΝΉ. and the amino group is blocked, if desired, by conventional blocking groups including particularly by protonation; mm) Cl XX' Cl CH-C-Cl OCH, 8 5 21 nn) HO it •CHG-C1 NH 0 Λ I II 0-C-CH2-NH-C-ra-C; .NH 'NH„ pp) (CH^CHCHgCHil-Cl °-fi qq) II -C-Cl - CH, I 5 NH2 as the hydrochloride, if desired wherein 3 represents 8 5 21 aiO or or 2 wherein R is hydrogen, hydroxy or acetoxy and R is 2 hydrogen, chloro or hydroxy when R is hydroxy and R is hydrogen when R^ is hydrogen or acetoxy; 2 wherein R is hydrogen, hydroxy or acetoxy and R is 2 hydrogen, chloro or hydroxy when R is hydroxy and R is hydrogen when R^ is hydrogen or acetoxy; or or 2 hydrogen, chloro or hydroxy when R is hydroxy and R is hydrogen when R1 is hydrogen or acetoxy? vv) 4-8521 CHC-C1 c=o I wherein R is hydrogen or methyl.
R , II ww) B-CH-C-C1 wherein B represents NH I C=0 I HLC-C-CH, Ρ I 3 Cl wherein R1 is hydrogen, hydroxy or acetoxy and R2 is 12 hydrogen, chloro or hydroxy when R is hydroxy and R is hydrogen when R^ is hydrogen or acetoxy. 4852 1 Acid chlorides are normally prepared under vigorous conditions, as by treatment of the acid at reflux with thionyl chloride, but when sensitive groups are present, including sensitive blocking groups, they can be prepared under practically neutral conditions by reaction of a salt of the acid with oxalyl chloride.
Description of the preferred embodiments In the Examples percentage compositions of solvent mixtures are by volume and purities are expressed as percentages by weight.
Proportions determined by NMR are expressed as mole percentages.
Example 1 To a mixture of 6-aminopenicillanic acid (6-APA) and 10 ml. CD2CI2 and 1,13 ml. trimethylchlorosilane at a temperature of 25-27°C there was added dropwise 1.23 ml. triethylamine over a period of thirty minutes. Stirring was continued for an additional two hours. Dry carbon dioxide gas was then bubbled into the mixture for about three hours. At the end of that period NMR (nuclear magnetic resonance) showed the presence of 6055 silylated carboxy 6-APA (SCA) having the structure The mixture was held in a refrigerator overnight. The next morning there was added 0.77 ml. N,N-dimethylaniline and the mixture was chilled to -8°C. There was then added 1.2 g of D-(-)-p-hydroxy-2-phenylglycyl chloride hydrochloride (79%) purity) in portions as follows: Time in Minutes Temp. °C Grams Added Zero -8 0.30 20 -4 0.30 40 -4 0.30 60 -4 0.30 120 +8 220 +15 310 +20 At the end of the 310 minutes of reaction thin layer chromatography (TLC) performed on a sample of the reaction mixture using a solvent system which was 60% ethyl acetate, 20% acetic acid and 20% water indicated the presence of amoxicillin.
To a cold, 2 ml. sample of the final reaction mixture there was added 1.0 ml. D2O. After separation by centrifugation the aqueous phase was found by NMR to contain 78% amoxicillin and about 20% 6-APA. The presence of amoxicillin was also confirmed by TLC.
Example 2 A mixture of 5.4 g. (0.025 mole) 6-aminopenicillanic acid and 6.2 ml. of 93% hexamethyldisilazane (HMDS; 0.0275 mole) and 0.07 g (about 0.001 mole) imidazole in 40 ml. CH2C12 was refluxed under nitrogen purge for about 17.5 hours. At the end of that period there was added 0.13 ml. (about 0.001 mole) trimethylchlorosilane (TMCS); the 8 3 2 1 solution became turbid. Reflux was continued for an additional 7 hours; deposits of NH^Cl were noted in the condenser. At that point NMR showed approximately 100% silylation of both the amino and the carboxyl group of the 6-APA. There was then added 0.2 ml. HMDS (0.00125 mole; about 5 mole %) and 0.06 ml. TMCS (about 0.0005 mole) and refluxing with nitrogen purging was continued for an additional 17 hours. At that time the NMR spectrum was the same as before with the addition of small amounts of HMDS and TMCS. Dry carbon dioxide was then bubbled into the reaction mixture at room temperature for 75 minutes; NMR then showed no HMDS and greater than 92% silylated carboxy 6-APA (SCA). There was then added 4.45 ml. Ν,Ν-dimethylaniline (DMA) (0.035 mole) and the mixture was chilled to -3° C. Then there was added 5.65 g. D-(-)-2-phenylglycyl chloride (95% purity; 0.026 mole) in portions as follows: Time in Temp. Grams Minutes °C. Added Zero -3 1.05 20 0 1.30 40 0 1.30 50 0 1.00 60 0 1.00 The reaction was followed by NMR which showed very little change at about 5 hours after the start of the reaction; the temperature was then 3° C. The reaction mixture was then kept packed in ice for the next 16 hours. It was then removed from refrigeration and stirred for 3.5 hours at room temperature (about 20-24° C.). A large amount of solid material was still present. The reaction mixture was then stirred at room temperature (22-24° C.) for about 63 hours. At the end of that time there was only slight turbidity. Upon D2O extraction of a sample NMR showed ampicillin and 6-APA.
The reaction mixture was chilled to about 0° C. and stirred 5 minutes in the cold after the addition of 35 ml. ice water. After polish filtration the mixture was washed with cold water and Cl^Clg. The aqueous phase, after separation, showed by TLC a large zone slower than ampicillin and 6-APA which represented New Intermediate X.
The aqueous phase was adjusted to pH 3.0 with NH^OH and seeded with ampicillin. Methyl isobutyl ketone (MIBK? 35 ml.) was added and the mixture was stirred, adjusted to pH 5.2 with more NH^OH, stirred at 20° C. for one hour, stirred in an ice-bath for another hour and refrigerated overnight. The precipitate of ampicillin was collected by filtration, washed first with 25 ml. cold water and then with 40 ml. MIBK and finally with 40 ml. of a mixture of 85 parts isopropyl alcohol and 15 parts water, dried at 50° C. and found to weigh 4.5 g with its identity as ampicillin confirmed by TLC31 8 5 21 Example 3 A mixture of 5.4 g. 6-APA, 6.2 ml. HMDS (93%) and 0.06 g. imidazole in 50 ml. CH2C12 was refluxed under nitrogen purge for 18 hours. There was then added 0.1 ml. TMCS which caused turbidity. Reflux for another two hours gave a clear solution with NH^Cl in the condenser. There was then added another 0.1 ml. TMCS leaving only very slight turbidity.
Reflux was continued without nitrogen purge for the next 65 hours. The mixture was then cooled to about 22° C. and dry carbon dioxide addition was begun. After 75 minutes NMR showed the formation of over 90% bis silylated carbamate (SCA). There was then added 4.45 ml. DMA and then 5.6 g. D-(-)-215 phenylglycyl chloride hydrochloride (97% purity) in portions as follows: Time in Temp. Grams Minutes °C. Added Zero 20 1.35 20 20 1.30 32 20 1.00 48 20 1.00 75 20 1.00 After this mixture had been stirred for an additional 17 hours TLC was run on samples of the reaction mixture and on diluted reaction mixture (1 ml. of reaction mixture diluted with 2 ml.
CH2C12) and showed in each a small zone of ampicillin and a large zone of New Intermediate X. 8 5 21 The reaction mixture was then chilled to 0° C., 40 ml. ice water was added and the mixture was stirred 5 minutes, polish filtered and washed with water and with CH2C12· The aqueous phase was separated, 10% was removed for sampling and the remainder was adjusted to pH 3.0 with NH^OH, seeded with ampicillin and stirred. After the addition of 40 ml. more MIBK the mixture was stirred and the pH adjusted to 5.2 with NH^OH and stirred at room temperature for one hour and then in an ice-bath for another hour. Crystals precipitated. After refrigeration overnight the crystalline product was collected by filtration, washed successively with MIBK, water and MIBK and then 40 ml. isopropanol-water (85-15) and dried at 45° C. to yield 6.25 g. ampicillin (6.8 g. corrected for sampling or a yield of 68%).
Example 4 To a mixture of 1,0 g. 6-APA and 1.13 ml.
TMCS in 10 ml. CD2C12 there was added dropwise, 1.23 ml. TEA over 30 minutes and the mixture was stirred for an additional two hours. Dry carbon dioxide was then bubbled in for four hours. At that time NMR showed about 55-60% carboxysilylation. The mixture was then held in the refrigerator overnight. In the morning 0.77 ml. DMA was added, the mixture was stirred, chilled to -8° C. and there was added 1.2 g D-(-)-p-hydroxy-2-phenylglycyl chloride hydrochloride in portions as follows: 8 5 2 1 Time in Minutes Temp. °C. Grams Added Zero -8 0.30 20 -4 0.30 40 -4 0.30 60 -4 0.30 120 8 220 15 310 20 At the end of 310 minutes NMR showed about 78% amoxi10 cillin and about 20% 6-APA.
Example 5 Dry 6-aminopenicillanic acid (10.0 g., 46.24 mmol., 1..0 eq.) was suspended in anhydrous methylene chloride (175 ml.) with stirring at 25° C. Triethylamine (10.76 g., 106.36 mmol., 2.30 eq.) was added at 25° C. followed by the addition of trimethylchlorosilane (11.70 g., 107.75 mmol., 2.33 eq.) over a 10-15 minute period maintaining the temperature below about 32° C. by the rate of addition of tri20 methylchlorosilane. After stirring for 20-30 minutes the mixture containing precipitated triethylamine hydrochloride was analyzed for complete silylation by 80 MHz NMR. The mixture was then gassed with carbon dioxide at 20° C. for about 2 hours and analyzed for complete carboxylation by 80 MHz NMR. Further gassing was sometimes necessary. The volume of the carboxylation mix was readjusted if necessary to about 175 ml. with dry methylene chloride. After carboxylation was complete the slurry was treated with propylene oxide (2.95 g., 3.56 ml., 50.87 mmol., 1.1 eq.) and cooled to 0-5° C. D-(-)-2-(p-Hydroxyphenyl)glycyl chloride hydrochloride hemidioxane solvate was added in 5 x 2.71 g. portions at about 2° C. (a total of 13.54 g. (50.87 mmol., 1.1 eq.) was added]. Each portion of acid chloride was allowed to dissolve* before the next portion was added. This required about 20 minutes per portion. Thi3 portion-wise addition was very important. The final acylation mix was examined for any undissolved acid chloride hydrochloride. The mix was held at 0-5° C. for 30 minutes and treated with cold (0-5° C.) deionized (DI) water (100 mis.) with high speed agitation for 10 minutes. The mix was allowed to separate and the lower phase methylene chloride was removed. The rich aqueous mix was polish filtered (very little solid) through a thin (**Dicalite) precoat of diatomaceous earth and the cake was washed with cold (0-5° C.) DI water (15 mis.). Any lower phase organic layer was removed prior to crystallization. The clear, light-yellow aqueous solution (pH 2-2.5) was adjusted to pH 3.5 at 0-5° C. and seeded if necessary. The slurry was held at 0-5° C. for 40 minutes and the pH adjusted to 4.8-5.0 with 6N ammonium hydroxide and crystallized for 2 hours. The slurry was filtered and ♦Stirring was stopped and the mixture examined for any solid at the bottom of the flask. Do not warm up slurry above 5° C. for this test or results will be erroneous.
**Dicalite is a trade mark 8 5 2 1 the solid amoxicillin thus collected was washed with a mixture of cold (0-5° C.) 1:1 isopropanol/ water and the cake was washed with methylene chloride (30 ml.) giving about 13.5 g. (about 70%) of snow-white amoxicillin trihydrate.
Example 6 6-Aminopenicillanic acid (108 g.; 0.5 mole), 1.0 g. imidazole (0.017 mole), 800 ml. dry methylene chloride and 120 ml. (0.56 mole) of HMDS (about 98% purity) was stirred and heated at reflux for 3.3 hours . The reaction was purged with dry nitrogen gas throughout the reflux to sweep out the NH^ formed in the reaction. Then 2.0 ml. of trimethylchlorosilane (TMCS) was added (0.016 mole). Reflux continued with N2 purging for an additional 19 hours and then the NH^Cl sublimed in the condenser was cleared out and 2.6 ml. TMCS (0.0206 mole) was added to the reaction. Reflux with N2 purging was continued for another 34 hours. The volume in the reaction mix was brought to 1000 ml. with dry methylene chloride. The NMR then showed 100% silylation of the amino and carboxyl group on the 6-aminopenicillanic acid. The solution was blanketed with N2 gas and held for nine days.
NMR confirmed the above and stability. The solution was stirred and CO2 was bubbled in for about 90 minutes. Temperature 20-22° C. NMR showed 100% conversion of the bis trimethylsilyl 6-aminoDenicillanic acid to the bis trimethylsiivlated of carbamate/6-aminopenicillanic acid (SCA) . 8 5 21 This master mix was used for the acylation experiments described below. The chemical in this solution had the formula carbamate of NMR showed the bis trimethylsilylated / 6-aminopenicillanic acid stable after nine days. 100 ml. of master mix (SCA equivalent to 10.8 g. 6-aminopenicillanic acid; 0.05 mole) was stirred at 22° C. and 8.0 g. TEA.HCI (0.058 mole) and 4.2 ml. of propylene oxide (0.06 mole) (See U.S. Patent 3,741,959) was added. Some TEA.HCI precipitated.
The mix was stirred and chilled to +3° C. 15.5 g. of D-(-)-p-hydroxyphenylglycyl chloride hydrochloride hemidioxane solvate (79% purity; 0.055 mole) was added to the reaction in portions as follows: Grams Added Time in Minutes Temp, °C. 3.0 Zero +3 3.0 7 +2 3.0 20 +2 6.5 33 +2 .5 8 5 21 After another seventy minutes about 50 ml. of dry methylene chloride was added to the reaction mixture to reduce the viscosity.
After another 160 minutes a 2 ml. sample was 5 removed and added to 1.0 ml. 0^0. After centrifugation NMR analysis of the aqueous phase indicated about 6% unacylated 6-aminopenicillanic acid.
Ten minutes later the reaction mixture was 10 transferred to a 600 ml. beaker and the transfer completed with 50 ml. methylene chloride wash.
While stirring in an ice bath there was added 60 ml. cold deionized ice water to provide a solution of two phases containing no solids and having pH 1.0. .0 ml. liquid anion exchange resin (LA-1) was added to the two phase system with stirring and seeding at pH 2.0. Crystallization began.
An additional 10.0 ml. LA-1 was added slowly over about 5 minutes. The pH was 3.0. There was then added 0.15 g. NaBH^. Then there was added 5.0 ml. LA-1; the pH was 4.5. Stirring was continued and there was added 1.0 g. NaHSO^ (sodium bisulfite) in 4.0 ml. water dropwise. There was then added 10.0 ml. LA-1; the pH continued to rise. Total LA-1 40 ml., final pH was 5.6. There was then added ml. acetone. At this point 1.5 g. NaHSO^ dissolved in 6.0 ml. water was added over 30 minutes. Stirring in the ice bath was continued. The precipitated product was collected by filtration and the cake washed successively with 50 ml. methylene chloride, 40 ml. water, 100 ml. isopropyl alcohol-water (80:20) and 100 ml. methylene chloride. The cake was then dried at atmospheric pressure and 45° C. to yield 18.2 g. of amoxicillin trihydrate which was a yield of 87% based on 6-aminopenicillanic acid? correcting for 1% sampling, the overall yield was about 88%.
LA-1 liquid anion exchange resin is a mixture of secondary amines wherein each secondary amine has the formula CH-C ( CH? ) 2CH2C (CH? JgCHg^CH-CHgNHC-R2 I3 R·5 3 wherein each of R , R and R is an aliphatic 12 3 hydrocarbon radical and wherein R , R and R contain in the aggregate from 11 to 14 carbon atoms; this particular mixture of secondary amines which is sometimes referred to as Liquid Amine Mixture No. I, is a clear amber liquid having the following physical characteristics: viscosity at 25° C. of 70 cps.; specific gravity at 20’ C. of 0.845; refractive index at 25° C. of 1.467; distillation range at 10 mm.: up to 160° C. - 4%, 160 to 210° C. - 5%, 210 to 220° C. - 74%, above 220° C. 17%. 8 5 2 1 Example 7 A methylene chloride solution (5.0 mis.) of trimethylsilyl 6-trimethylsilyloxycarbonylaminopenicillinate (0.54 g., 2.497 mmol.) was treated with triethylamine hydrochloride (0.20 g., 1.45 mmol.) followed by propylene oxide (0.162 g., 2.75 mmol.) at 25° C. The mixture was stirred at 25° C for 20 minutes to facilitate the solution of most of the triethylamine hydrochloride. Phenoxyacetyl chloride (0.43 g., 2.75 mmol.) was added dropwise at 25° C. and the mixture stirred at 25° C. for 30 minutes. A sample was removed and analyzed by CMR at 20.0 MHz. CMR (carbon-13 nuclear magnetic resonance spectroscopy) data showed the complete disappearance of phenoxyacetyl chloride and the APA carbamate and the appearance of penicillin V trimethylsilyl ester. The presence of penicillin V trimethylsilyl ester was proved by spectral comparison with an identical sample prepared by silylation of penicillin V free acid with triethylamine and trimethylchlorosilane. The yield estimated from the CMR spectrum was 85 to 90%.
Similarly prepared using the same molar quantities of reagents and the appropriate acid chloride were cloxacillin, dicloxacillin, staphcillin and nafcillin. CMR data on these acylation mixes shewed an extremely clean acylation mix with yields estimated to be at least 85%.
Example 8 Reaction according to the above procedures of a compound having the formula (CH3)3Si-O-C-NH= = <= ZCH, = 3 CHΌ-Β wherein B is an easily cleavable ester protecting group selected from the group consisting of trimethylsilyl, benzhydryl, benzyl, p-nitrobenzyl, p-methoxybenzyl, trichloroethyl, phenacyl, acetonyl, methoxymethyl, 5indanyl, 3-phthalidyl, l-[(ethoxycarbonyl)oxyjethyl, pivaloyloxymethyl and acetoxymethyl with a reagent which is the appropriate acid chloride or acid chloride hydrochloride, said reagent containing blocking groups as necessary, followed by removal of any blocking groups whose removal is desired produces the following com15 pounds: almecillin; armecillin, azidocillin: azlocillin; bacampicillin; Bay K 4999 having the formula 8 5 2 1 BL-P1654 having the formula <χ Λ—CH - CONH—,— w 1 NH 0' NH O=C-NH-C NH„ rV CH, COOH BL-P1908 having the formula carfecillin; carindacillin; cyclacillin; clometocillin; cloxacillin; dicloxacillin; EMD-32412 having the formula 8 5 21 epicillin; floxacillin (flucloxacillin); furbucillin; hetacillin; I.S.F.-2664 having the formula isopropicillin; methicillin; mezlocillin; nafcillin; 5 oxacillin; phenbenicillin; PC-455 having the formula apareillin (PC-904) having the formula piperacillin; 3,4-dihydroxypiperacillin; pirbenicillin; 10 pivampicillin; PL-385 having the formula „ 48521 prazocillin; sarmoxicillin; sarpicillin; ticarcillin cresyl sodium; ticarcillin; carbenicillin; carfecillin; fibracillin and Bay-e-6905 having the formula •-IIH This invention is capable of industrial application.

Claims (25)

1. Α comp'>,i;id n.iviny tin· 1‘iiiiuiia: (/#3? 3 wherein 5 Bis an easily cleavable ester protecting group.
2. A compound as claimed in claim 1 (C« 3 i-O-C-NHHV 3 1 CH. \-5 wherein B is a trimethylsilyl, benzhydryl, benzyl, p-nitrobenzyl, p-methoxy-ben;;yl, trichloroethyl, phenacyl, 10 acetonyl, methoxymethyl, 5-indanyl, 3-phthalidyl, - 48521 1- [(ethoxycarbony1)oxy]ethyl, pivaloyloxymethyl or acetoxymethyl group.
3. A compound having tho formula:
4. A process the formula: for the production of a compound of II Si-O-C-NH· (ch 3 ) 3 '''Ό- a wherein B is an easily cleavuble ester protecting group v/hich comprises adding dry carbon dioxide to a solution of a compound having the formula: CH CH3 ^-Ό-Β wherein Β is as defined above in an anhydrous inert organic solvent at a temperature in the range of from 0°C to 100°C until completion of the reaction.
5. 5. A process as claimed in claim 4 wherein B is a trimethylsilyl, benzhydryl, benzyl, p-nitrobenzyl, p-methoxybenzyl, trichloroethyl, phenacyl, acetonyl, methoxymethyl, 5-indanyl, 3-phthalidyl, 1-Q(ethoxycarbonyl)oxy3ethyl, pivaloyloxymethyl or 10 acetoxymethyl group.
6. A process as claimed in claim 4 or claim 5 wherein B is a trimethylsilyl group.
7. A process as claimed in any one of claims 4 to 6 wherein the reaction is carried out at room 15 temperature. 4 8 5 2 1
8. Λ μ rocess aa claimed in any one of claims 4 to 7 wherein the reaction is carried out in methylene chloride.
9. A process for the production of a conventional penicillin having the formula : wherein is the residue after removal of the hydroxyl group of an organic carboxylic acid containing from two to twenty carbon atoms, which process comprises the consecutive steps of acylating in an anhydrous inert organic 10. Solvent, a silylated compound having the formula: II CCH 3 ? 3 Si-O-C-NH: e .CH, rV 3 ! CH. ''''O-B 4 8 5 21 wherein B is an easily cleavable ester protecting group with an equimolar amount of the acid chloride of the said carboxylic acid, and then converting the group B to a hydrogen atom.
10. a process as claimed in claim 9, wherein the 5 organic solvent is methylene chloride.
11. · A process as claimed in any one of claims 9 or 10 wherein the reaction is carried out in the presence of a weak base,
12. a process as claimed in claim 11 wherein the 10 weak base is propylene oxide,
13. A process as claimed in any one of claims 10 to 12 wherein the reaction is carried out at about 2O°C.
14. a process as claimed in any one of claims 9 to 15. 13 wherein the silylated compound has been produced by a process as claimed in any one of claims 4 to 3.
15. A process for tho production of a 6-gl-aminoarylacetamidopenieillanic acid which comprises reacting a compound of the formula: 4 8 5 2 1 (CH^Si-O-C-NH-CH—CH 1-N— H'S - CH C-O-SitCHj) 3 in an anhydrous inert organic solvent with an approximately equimolar weight of a D-(-)-(^-aminoarylacetyl chloride hydrochloride. 5
16. A process for the production of amoxicillin which comprises reacting a compound of the formula: (CH-)-Si-O-C-HH-CH 1 o’a / CH 5 Γ X CH 5 Ii-CH C-O-Si(CH,), Il 3 0 in an anhydrous inert organic solvent with an approximately equimolar weight of D-(-)-2-p-hydroxyphenylglycyl 10 chloride hydrochloride.
17. , A process for the production of ampicillin which comprises reacting a compound of the formula: « /% (CH^Si-O-C-HH-CH— CH <1 ' J - CH I C-O-Si(CH*)_ II ·? in an anhydrous inert organic solvent with an approximately e-gu.molar weight of D-(-)-2-phenylglycyl chloride hydrochloride.
18. A process as claimed in any one of claims 15 to 17 wherein the reaction is carried out at a temperature above -10°C.
19. A process as claimed in claim 4 substantially as hereinbefore described with reference to any one of Examples 1 to 6.
20. a compound as claimed in claim 1 whenever produced by a process as claimed in ίny one of claims 4 to 3, or claim 1921. A process as claimed in claim 9 substantially as hereinbefore described with reference to any one of Examples 1 to 8. 4 8 5
21
22. A penicillin having the formula: o wherein R-C- is the residue after removal of the hydroxyl group of an organic carboxylic acid containing from two 5 to twenty turbon atoms, whenever produced by a process as claimed in any one of claims 9 to 14 or claim 21.
23. /. 6-C(-aminoarylacetamidopenicillanic acid whenever produced by a. process as claimed in claim 15.
24. Amoxicillin whenever produced by a process 10 as claimed in claim 16.
25. Ampicillin whenever produced by a process as claimed in claim 17.
IE1283/79A 1978-12-18 1979-08-08 6-trimethylsilyloxycarbonyl penicillanic acid esters and the production of penicillins therefrom IE48521B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97070478A 1978-12-18 1978-12-18
US478079A 1979-01-19 1979-01-19
US06/021,852 US4240960A (en) 1979-03-19 1979-03-19 Trimethylsilyl substituted penicillins

Publications (2)

Publication Number Publication Date
IE791283L IE791283L (en) 1980-06-18
IE48521B1 true IE48521B1 (en) 1985-02-20

Family

ID=27357705

Family Applications (1)

Application Number Title Priority Date Filing Date
IE1283/79A IE48521B1 (en) 1978-12-18 1979-08-08 6-trimethylsilyloxycarbonyl penicillanic acid esters and the production of penicillins therefrom

Country Status (20)

Country Link
AR (1) AR225898A1 (en)
AT (1) AT364849B (en)
AU (1) AU531779B2 (en)
CA (1) CA1141752A (en)
CH (1) CH642972A5 (en)
DK (2) DK160613C (en)
ES (2) ES482986A1 (en)
FI (1) FI69846C (en)
FR (1) FR2444683A1 (en)
GB (1) GB2037275B (en)
GR (1) GR73899B (en)
IE (1) IE48521B1 (en)
IL (1) IL57909A (en)
IT (1) IT1117760B (en)
LU (1) LU81432A1 (en)
NL (1) NL171271C (en)
NO (1) NO158541C (en)
PH (1) PH16327A (en)
SE (2) SE436281B (en)
YU (1) YU221082A (en)

Also Published As

Publication number Publication date
LU81432A1 (en) 1980-01-22
IL57909A (en) 1983-05-15
NL171271B (en) 1982-10-01
FR2444683A1 (en) 1980-07-18
AR225898A1 (en) 1982-05-14
NL7904805A (en) 1980-06-20
SE448630B (en) 1987-03-09
IL57909A0 (en) 1979-11-30
SE8401182L (en) 1984-03-02
IT7949919A0 (en) 1979-08-01
IT1117760B (en) 1986-02-24
FR2444683B1 (en) 1983-06-17
AT364849B (en) 1981-11-25
ES490644A0 (en) 1981-04-01
FI69846C (en) 1986-05-26
DK143990D0 (en) 1990-06-13
DK160613B (en) 1991-04-02
FI791732A (en) 1980-06-19
NO158541C (en) 1988-09-28
YU221082A (en) 1983-04-30
DK162055C (en) 1992-02-10
CH642972A5 (en) 1984-05-15
SE436281B (en) 1984-11-26
AU4777479A (en) 1980-06-26
GR73899B (en) 1984-05-18
DK213779A (en) 1980-06-19
ATA421579A (en) 1981-04-15
NL171271C (en) 1983-03-01
SE7904483L (en) 1980-06-19
IE791283L (en) 1980-06-18
DK160613C (en) 1991-09-23
AU531779B2 (en) 1983-09-08
ES8104301A1 (en) 1981-04-01
ES482986A1 (en) 1980-09-01
GB2037275B (en) 1983-01-19
NO791823L (en) 1980-06-19
FI69846B (en) 1985-12-31
DK162055B (en) 1991-09-09
GB2037275A (en) 1980-07-09
PH16327A (en) 1983-09-05
NO158541B (en) 1988-06-20
DK143990A (en) 1990-06-13
CA1141752A (en) 1983-02-22
SE8401182D0 (en) 1984-03-02

Similar Documents

Publication Publication Date Title
EP0019345B1 (en) Process for the preparation of a (d-alpha-amino-(p-hydroxyphenyl)-acetamido) group containing cephalosporanic acid derivatives
JP2766116B2 (en) New production method of cephalosporins and new intermediates
US4351766A (en) Production of penicillins
US4240960A (en) Trimethylsilyl substituted penicillins
IE48521B1 (en) 6-trimethylsilyloxycarbonyl penicillanic acid esters and the production of penicillins therefrom
JPS6111958B2 (en)
US4223135A (en) Production of cephalosporins
US4310458A (en) Production of penicillins
US4278600A (en) Production of penicillins
KR850001229B1 (en) Process for preparing 6- -aminoarylacetamido penicillanic acid
US4316017A (en) Cephalosporin intermediates
HU185445B (en) Process for preparing panam-carboxylic acid derivatives
US4316016A (en) Cephalosporin intermediates
KR800000789B1 (en) Process for the preparation of novel amino acids
BE879784A (en) PRODUCTION OF CEPHALOSPORINS
JPS5829790A (en) Manufacture of desacetoxycephalosporanic acid
NO160210B (en) N-TRIMETHYLSILYLOXYCARBONYL-6-AMINOPENICILLIN INTERMEDIATE FOR THE PREPARATION OF A PENICILLIN.
IE50135B1 (en) Process for the preparation of a(d-a-amino-(p-hydroxyphenyl)-acetamido)cephalosporanic acid derivatives

Legal Events

Date Code Title Description
MM4A Patent lapsed